Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.39 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | BCR | P11274 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CCR4 | P51679 | 6/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641805 | 1.00 | ALDH1A1 (0.43) | ALDH1A1KDM4ESMN1; SMN2GAAPIN1 | |
| SCHEMBL5258785 | 0.81 | PIN1 (0.45) | ALDH1A1SMN1; SMN2PIN1CYP1A2MEN1 | |
| SCHEMBL2966721 | 0.80 | CDK1 (0.42) | ALDH1A1KDM4ESMN1; SMN2GAAPIN1 | |
| SCHEMBL31634163 | 0.79 | GAA (0.36) | ALDH1A1KDM4ESMN1; SMN2GAAPIN1 | |
| SCHEMBL1981633 | 0.78 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2GAAPIN1 | |
| SCHEMBL16674677 | 0.78 | KDM4E (0.44) | ALDH1A1KDM4ESMN1; SMN2GAAPIN1 | |
| SCHEMBL1996295 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KDM4ESMN1; SMN2GAAPIN1 | |
| SCHEMBL2437490 | 0.77 | ALDH1A1 (0.53) | ALDH1A1KDM4ESMN1; SMN2GAAPIN1 | |
| SCHEMBL13004012 | 0.77 | GAA (0.40) | ALDH1A1GAAULK1KMT2ACCR4 | |
| SCHEMBL31366250 | 0.77 | GAA (0.40) | ALDH1A1GAAULK1KMT2ACCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 404 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744661-A2 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20260027104-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4680226-A2 | ACYLSULFONAMIDE KAT6A INHIBITORS | Olema Pharmaceuticals, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS INC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2025243044-A1 | COMPOUNDS | Pheno Therapeutics Limited (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-20250361238-A1 | 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER | SOPONPONG JAKAPUN (TH) | 2025-11-27 | — | — | US | disclosed |
| EP-4298092-B1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| US-12466805-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| EP-2022785-A1 | Alkynylpyrimidines as Tie2 kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-11 | — | — | EP | disclosed |
| WO-2009001127-A1 | CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155140-A1 | ALKYNYLPYRIMIDINES AS TIE2 KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155572-A2 | FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
| US-20080064696-A1 | SUBSTITUTED SULPHOXIMINES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-13 | — | — | US | disclosed |
| WO-2008006560-A1 | SUBSTITUTED SULPHOXIMINES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-01-17 | — | — | WO | disclosed |
| EP-1856058-A2 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006094187-A2 | PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | AMGEN INC. (US) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199817-A1 | Phthalazine, aza- and diaza-phthalazine compounds and methods of use | DAPK2, CDK2, DAPK1 | ALDH1A1 1599/4885KDM4E 929/4885SMN1; SMN2 4540/4885 |
| US-12466805-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | ALDH1A1 621/4885KDM4E 659/4885SMN1; SMN2 2586/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | ALDH1A1 4050/4885KDM4E 3284/4885SMN1; SMN2 787/4885 |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | ALDH1A1 442/4885KDM4E 2357/4885SMN1; SMN2 764/4885 |
| US-20260027104-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | CBR3, HAX1, CBR1 | ALDH1A1 2920/4885KDM4E 1320/4885SMN1; SMN2 4351/4885 |
| US-20250361238-A1 | 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER | PDCD1, CD274, PDCD1LG2 | ALDH1A1 36/4885KDM4E 805/4885SMN1; SMN2 2854/4885 |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | ALDH1A1 1068/4885KDM4E 773/4885SMN1; SMN2 3098/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | ALDH1A1 4061/4885KDM4E 3320/4885SMN1; SMN2 782/4885 |
| US-20080064696-A1 | SUBSTITUTED SULPHOXIMINES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | TIE1, KDR, TEK | ALDH1A1 2471/4885KDM4E 293/4885SMN1; SMN2 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.